ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL

During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) treatment in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

In this interview, Abdulhaq discusses 3-year follow-up results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs rituximab (R)-GemOx in patients with R/R DLBCL who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT). They also discuss the efficacy and safety of Glofit-GemOx in clinically relevant patient subgroups.

Key points

• With 3 years of follow-up, the benefit of Glofit-GemOx vs R-GemOx was sustained, with an improved complete response (CR) rate of 58.5% vs 25.3%.¹
• The median overall survival (OS) was 25.5 months in the Glofit-GemOx arm vs 12.5 months in the R-GemOx arm.¹
• In the landmark analysis of patients who had a CR at the end of Glofit-GemOx treatment, the progression-free survival and OS rates 24 months after end of treatment were 74.2% and 79.4%, respectively.¹
• The benefit of Glofit-GemOx vs R-GemOx was more pronounced in patients treated in the second-line (2L) setting (36-month OS rate, 54.6%; 30-month PFS rate, 41.5%).¹
• There were no new safety signals; the most common adverse events (AEs) were gastrointestinal disorders and cytopenias.¹
  • There were more Grade 3–5 infections in the Glofit-GemOx arm vs R-GemOx (19.8% vs 12.5%).¹
  • Any-grade and Grade 3 cytokine release syndrome (CRS) occurred in 44.8% and 2.3% of patients, respectively.¹
• The subgroup analysis from the STARGLO trial assessed outcomes in patients stratified by age, lines of therapy, and time of relapse.²
• A sustained benefit with Glofit-GemOx vs R-GemOx was observed across age groups, including patients aged <65 years (median OS, 27.0 months vs 9.0 months), aged ≥65 years (median OS, 25.0 months vs 13.8 months), and aged ≥75 years (median OS, 33.0 months vs 8.3 months).²
• Improved OS and higher CR rates were observed in patients who were treated with Glofit-GemOx vs R-GemOx in the 2L setting, regardless of whether they had early or late relapse.²
  • The 36-month OS rates were 46.1% vs 16.5% and 76.8% vs 60.0% in the early- and late-relapse groups, respectively.²
  • The CR rates were 56.0% vs 16.7% and 83.9% vs 47.6% in the early- and late-relapse groups, respectively.²
• The safety profile was similar between the patient subgroups, with more infections in patients aged ≥75 years.²

Results from these analyses of the STARGLO trial demonstrated that Glofit-GemOx is associated with improved outcomes vs R-GemOx in patients with R/R DLBCL who are ineligible for auto-HSCT.^1,2 The 3-year follow-up data showed that the benefit of Glofit-GemOx is sustained with longer follow-up.¹ The benefit of Glofit-GemOx was shown regardless of age and time of relapse, with a more pronounced benefit observed in patients treated in the 2L setting.^1,2 Taken together, these results support the use of Glofit-GemOx as an off-the-shelf treatment option with curative potential in this patient population. 

This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.